
LRMR Stock Forecast & Price Target
LRMR Analyst Ratings
Bulls say
Larimar Therapeutics has demonstrated significant improvements in its lead product candidate, CTI-1601, with median frataxin (FXN) expression rising from 2.7 pg/ug at baseline to 13.44 pg/ug at six months, surpassing the levels observed in over 50% of healthy volunteers. Additionally, the company reported a median improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) of -2.20 points, contrasting sharply with the predicted decline of +1.00 in the FACOMS natural history cohort over the same period. These positive clinical outcomes suggest a strong efficacy profile for CTI-1601, potentially bolstering investor confidence in Larimar Therapeutics's future performance.
Bears say
The financial outlook for Larimar Therapeutics is negatively impacted by a significant decline in their projected revenues, with FY29 estimates revised downward from $659 million to $407 million, indicating a potential shift in market expectations. Furthermore, the clinical data reflects concerning trends, as the median mFARS change of -2.20 points demonstrates a less favorable outcome compared to an observed improvement in the FACOMS natural history population, which recorded a +1.00 point change. These factors contribute to heightened skepticism regarding the efficacy of Larimar Therapeutics's lead product candidate, CTI-1601, and its potential market performance in treating Friedreich's ataxia.
This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LRMR Analyst Forecast & Price Prediction
Start investing in LRMR
Order type
Buy in
Order amount
Est. shares
0 shares